News Feature

Filter By:

Article Type
  • Funding for early-stage projects and global collaborations are aiming to breathe life into the fragile ecosystem for novel antibiotics.

    • Raveena Bhambra
    News Feature
  • In the past decade, deals involving rare diseases have increased in size and value, supported by the growing number of opportunities based on novel therapeutic platforms.

    • Raveena Bhambra
    • DealForma, LLC
    News Feature
  • We present a round up of selected biopharma, biotechnology and drug discovery stories published in September 2021 across the Springer Nature portfolio of journals.

    • Raveena Bhambra
    News Feature
  • Next-generation immuno-oncology targets continue to catalyze major deals, exemplified by the race to develop inhibitors of the immune checkpoint TIGIT.

    • Raveena Bhambra
    News Feature
  • After an unusual year, M&A activity picked up again in the biopharma industry with a number of billion-dollar deals.

    • Biopharma Dealmakers
    News Feature
  • COVID-19 has accelerated development and awareness of next-generation therapeutics, including mRNA vaccines, boosting the field’s dealmaking and investment activities.

    • Paul Verdin
    • Tsz Mon Tsang
    News Feature
  • This month we showcase the six-part Nature Careers podcast series, ‘Business of Science,’ which ran in May and June 2021 and aimed to teach new entrepreneurs about the first steps of research commercialization, from registering a patent, to scaling up and beyond.

    • Raveena Bhambra
    News Feature
  • Big pharma dealmaking returns to pre-pandemic levels as companies spend big to develop a range of cancer therapies.

    • Raveena Bhambra
    News Feature
  • Welcome to our May selection of key business of science stories from across Springer Nature’s portfolio of journals. This month we explore some stories based around COVID vaccines and bring to you the first two series of a Nature Careers ‘Business of Science’ podcast that aims to teach new entrepreneurs the first steps of research commercialization and patenting.

    • Raveena Bhambra
    News Feature
  • Plentiful financing and multiple pharma partnerships illustrate the burgeoning interest in applying artificial intelligence tools to drug research and development.

    • Neil Savage
    News Feature
  • Approaches such as gene therapy and nucleic acid-based therapies are emerging in recent deals related to potential treatments for ophthalmic diseases.

    • Biopharma Dealmakers
    News Feature